SKINBIOTHERAPEUTICS PLC Logo

SKINBIOTHERAPEUTICS PLC

SBTX | IL

Overview

Corporate Details

ISIN(s):
GB00BF33H870
LEI:
213800YMQOCB23FX6I06
Country:
United Kingdom
Address:
THE CORE, NE4 5TF NEWCASTLE UPON TYNE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

SkinBioTherapeutics PLC is a life science company advancing skin health through microbiome science. Its core activities center on the proprietary SkinBiotix® platform, a technology from The University of Manchester that harnesses the microbiome to protect and restore skin. The company commercializes its technology via in-house product development, such as the AxisBiotix probiotic food supplement for psoriasis, and through strategic acquisitions. Its subsidiaries, including Dermatonics and Bio-Tech Solutions, provide established product lines in dermatological and foot care, as well as formulation, manufacturing, and packaging services. SkinBioTherapeutics targets applications across five key sectors: Cosmetics, Food Supplements, Medical Devices, Hygiene, and Pharmaceuticals.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for SKINBIOTHERAPEUTICS PLC. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 08:00
Earnings Release
FY Trading Update
English 21.6 KB
2025-06-30 08:00
Regulatory News Service
Croda Commercial Launch Progressing as Expected
English 16.2 KB
2025-06-27 08:00
Regulatory News Service
Notice of IMC Shareholder Presentation
English 15.4 KB
2025-06-25 12:28
Major Shareholding Notification
Holding(s) in Company
English 22.0 KB
2025-06-20 08:00
Share Issue/Capital Change
Result of WRAP Retail Offer
English 28.1 KB
2025-04-07 18:34
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-03-26 08:00
Earnings Release
Half-year Report
English 194.4 KB
2025-02-26 10:00
Major Shareholding Notification
Holding(s) in Company
English 21.9 KB
2025-02-24 08:00
Declaration of Voting Results & Voting Rights Announcements
Exercise of Warrants and Total Voting Rights
English 16.2 KB
2024-12-27 12:00
Post-Annual General Meeting Information
Result of AGM
English 11.5 KB
2024-12-12 15:45
Major Shareholding Notification
Holding(s) in Company
English 75.3 KB
2024-12-04 16:55
Report Publication Announcement
Posting of Annual Report and Notice of AGM
English 10.8 KB
2024-12-04 16:54
Earnings Release
Final Results
English 755.0 KB
2024-12-04 08:00
Report Publication Announcement
Notice of Results
English 11.9 KB
2024-11-29 12:00
Report Publication Announcement
Notice of Results
English 12.0 KB

Automate Your Workflow. Get a real-time feed of all SKINBIOTHERAPEUTICS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SKINBIOTHERAPEUTICS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ONCODESIGN Logo
Develops precision cancer therapies and diagnostics targeting resistance and metastasis.
France ALONC
Oncodesign Precision Medicine S.A Logo
Develops therapies & diagnostics for resistant and metastatic cancers.
France ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiopharmaceuticals like Radspherin® for localized cancer treatment.
Norway OCIN
OncoZenge AB Logo
Developing a non-opioid lozenge for oral pain relief in cancer patients.
Sweden ONCOZ
Onxeo Logo
Developing precision therapies for complex diseases using a proprietary single-domain antibody platform.
France ALONX
OPTIBIOTIX HEALTH PLC Logo
Develops microbiome-modulating ingredients and supplements to manage chronic lifestyle diseases.
United Kingdom OPTI
Oramed Pharmaceuticals Inc. Logo
Developing oral drug delivery systems to replace injections, like an oral insulin capsule.
Israel ORMP
Oryzon Genomics S.A. Logo
Advancing epigenetic therapeutics for oncology and central nervous system disorders.
Spain ORY
OSE Immunotherapeutics Logo
Developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation.
France OSE
Ovoca Bio Plc Logo
Clinical-stage biopharma developing novel treatments for female sexual dysfunction.
Ireland OVXA